Glimepiride
Brand names: Glimepiride
At a glance
- Medicare prescriptions, 2024
- 4,052,064
- Medicare drug cost
- $36.5M
- Average cost per prescription
- $9.00
- Clinicians who prescribed it
- 90,688
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
Glimepiride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use Glimepiride tablets should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis, as it would not be effective in these settings.
From the FDA-approved prescribing information (label dated March 2026). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Family Medicine 34.0%
- Internal Medicine 30.5%
- Nurse Practitioners 14.9%
- Endocrinology & Diabetes 8.6%
- Physician Assistants 4.5%
- General Practice 4.0%
- Geriatric Medicine 1.0%
- Cardiology 0.5%
- Nephrology (Kidney) 0.4%
- Hospitalist 0.2%
- Pediatrics 0.1%
- Pulmonology 0.1%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions fell 22% from 2019 to 2024.
Biggest change by state since 2019
- New Hampshire −13%
- Kansas −15%
- Florida −15%
- South Dakota −15%
- Puerto Rico −16%
- Colorado (smallest change) −41%
- Oregon (smallest change) −40%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 3 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Aurobindo Pharma Limited
| Strength | Looks like | Imprint |
|---|---|---|
| 1 mg | pink oval tablet, 10 mm, scored to split in 2 | X 76 |
| 2 mg | green oval tablet, 10 mm, scored to split in 2 | Y 32 |
| 4 mg | blue oval tablet, 10 mm, scored to split in 2 | Y 34 |
Pd-Rx Pharmaceuticals, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 4 mg | blue oval tablet, 8 mm, scored to split in 2 | RDY 322 |
Remedyrepack Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 1 mg | pink oval tablet, 8 mm, scored to split in 2 | I 1 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
3 recalls since 2020
- Jan 2024 · Dr. Reddy's Laboratories, Inc. · Class III
Misprint on tablet - Mar 2023 · Northwind Pharmaceuticals LLC · Class II
CGMP Deviations - Feb 2023 · Accord Healthcare, Inc. · Class II
CGMP Deviations: recalling drug products following an FDA inspection.
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.